Epitope mapping studies with human anti-cytochrome P450 3A antibodies.
A subset of patients with hypersensitivity reactions to the aromatic anticonvulsants phenytoin, carbamazepine, and phenobarbital have circulating antibodies that recognize members of the rat cytochrome P450 (CYP) 3A subfamily. These antibodies do not recognize related human CYP3A proteins despite the high degree of structural similarity. To investigate the relationship between P450-mediated drug metabolism and the development of anti-P450 antibodies, we initiated epitope mapping studies by screening a library of fusion proteins constructed from rat CYP3A1 with an anti-CYP3A1-positive patient serum sample. Positive signals from colony lifts were confirmed by sodium dodecyl sulfate/polyacrylamide gel electrophoresis and immunoblotting, and a 26-amino acid sequence corresponding to amino acids 342-367 of the CYP3A1 protein (NKAPPTY-DTVMEMEYLDMVLNETLRL) was identified as containing the epitope recognized by IgG3 antibodies in this serum sample. By subjecting inserts from two clones into a second round of library construction and screening by immunoblot analysis, we further defined the epitope to EYLDMVLNETLRL. Single amino acid deletions identified DMVLNETLRL as the minimum amino acid sequence required for antibody binding. The corresponding sequence in the four human CYP3A proteins differs by only one amino acid (DMVVNETLRL) This amino acid is critical to antibody recognition as immunoreactivity of the L361V mutant is markedly reduced. Anti-CYP3A antibodies in nine of nine additional sera also recognized the 13-amino acid epitope; for five of these sera, the minimum antibody binding sequence was DMVLNETLRL. The proximity of this epitope to a region determining substrate specificity may provide the link among reactive metabolite production, hapten formation, and the production of anti-P450 antibodies in anticonvulsant-induced idiosyncratic reactions.
Leeder
J S
JS
Department of Pediatrics, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.
Gaedigk
A
A
Lu
X
X
Cook
V A
VA
D000595:Amino Acid Sequence; D000818:Animals; D000906:Antibodies; D000927:Anticonvulsants / Q000009:adverse effects / Q000276:immunology; D001483:Base Sequence; D001666:Binding Sites, Antibody; D015153:Blotting, Western; D016384:Consensus Sequence; D019392:Cytochrome P-450 CYP2E1; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis / Q000737:chemistry* / Q000276:immunology*; D017931:DNA Primers; D004342:Drug Hypersensitivity; D004591:Electrophoresis, Polyacrylamide Gel; D000939:Epitopes / Q000032:analysis*; D015723:Gene Library; D006241:Haptens; D006801:Humans; D007150:Immunohistochemistry; D006899:Mixed Function Oxygenases / Q000096:biosynthesis / Q000737:chemistry* / Q000276:immunology*; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000032:analysis / Q000276:immunology; D016133:Polymerase Chain Reaction; D051381:Rats; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000737:chemistry / Q000276:immunology; D017386:Sequence Homology, Amino Acid
D000906:Antibodies; D000927:Anticonvulsants; D017931:DNA Primers; D000939:Epitopes; D006241:Haptens; D010446:Peptide Fragments; D011994:Recombinant Proteins; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D019392:Cytochrome P-450 CYP2E1